H&R Aktie

H&R für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2E4T7 / ISIN: DE000A2E4T77

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
25.07.2025 08:53:24

EQS-Adhoc: H&R GmbH & Co. KGaA: Publishing of preliminary Figures for First Half of 2025

EQS-Ad-hoc: H&R GmbH & Co. KGaA / Key word(s): Half Year Results/Preliminary Results
H&R GmbH & Co. KGaA: Publishing of preliminary Figures for First Half of 2025

25-Jul-2025 / 08:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Insider information pursuant to Article 17 of the Market Abuse Regulation [MAR] 

H&R GmbH & Co. KGaA: Preliminary Figures for First Half of 2025

  • Sales revenues reach EUR 653.1 million (HY1-2024: EUR 675.6 million)
  • EBITDA at EUR 40.1 million slightly below previous year (HY1-2024: EUR 41.1 million)

Salzbergen, Germany, July 25, 2025. H&R GmbH & Co. KGaA (H&R KGaA for short; ISIN DE000A2E4T77) reported stable financial figures overall at the end of the first half of 2025. According to preliminary calculations, consolidated operating earnings (EBITDA – consolidated earnings before income taxes, other financing income and expenses, as well as depreciation, amortization, impairment losses, and write-ups on intangible assets and property, plant, and equipment) amounted to EUR 17.8 million in the second quarter according to preliminary calculations, thus failing to match the momentum seen at the start of the year (Q1-25: EUR 22.4 million) nor that of the same quarter of the previous year 2024 (Q2-24: EUR 19.8 million). The results for the second quarter also fell short of expectations at other levels: EBIT closed at EUR 3.1 million, down from EUR 4.9 million last year, mainly as a result of consistently high depreciation and amortization and higher operating expenses. Earnings before taxes (EBT) amounted to EUR 0.2 million in the second quarter of 2025 (Q2-2024: EUR 1.7 million). Consolidated net income attributable to shareholders amounted to EUR -1.6 million (Q2-2024: EUR 1.3 million). Earnings per share thus showed a loss of EUR -0.04. Sales revenue in the second quarter of the current fiscal year declined to EUR 307.3 million (Q2-2024: EUR 338.6 million) due to lower raw material prices.

Looking at the first half of 2025 as a whole, the company provisionally achieved a slightly lower operating result (EBITDA) of EUR 40.1 million (first half of 2024: EUR 41.1 million). With depreciation and amortization remaining virtually unchanged from the previous year, the other results for the six-month period were partly at the previous year's level: EBIT amounted to EUR 10.9 million (first half of 2024: EUR 11.7 million). Earnings before taxes (EBT) were also slightly weaker at EUR 4.9 million (first half of 2024: EUR 5.3 million). Consolidated net income attributable to shareholders, on the other hand, closed at a significantly reduced EUR 0.3 million (first half of 2024: EUR 2.8 million) due to significantly higher tax expenses. Benefiting exclusively from the better first quarter of 2025, H&R KGaA generated earnings per share of EUR 0.01 at the end of the first half of the year. At the end of the first half of the year, sales revenues amounted to EUR 653.1 million (first half of 2024: EUR 675.6 million).

The ChemPharm Refining segment made a significant contribution to the quarterly and half-year results. Operating earnings improved in the second quarter of 2025 to EBITDA of EUR 13.0 million (Q2-2024: EUR 10.1 million). For the six-month period, the segment also accounted for the larger share of earnings at EUR 26.9 million (first half of 2024: EUR 20.6 million) and, in addition, reported a significant improvement in earnings compared with the same period of the previous year. Sales revenues in the segment were down on the previous year due to raw material prices, reaching EUR 405.9 million for the first half of the year (first half of 2024: EUR 417.0 million).

 

The situation was different in the ChemPharm Sales segment: although it was still a key earnings driver last year, EBITDA contributions of EUR 8.1 million (Q2-2024: EUR 10.1 million) and EUR 17.8 million (first half of 2024: EUR 21.1 million) were down on the previous year. Sales revenues also declined, amounting to EUR 113.4 million in the second quarter of 2025 (Q2-2024: EUR 120.7 million) and EUR 237.1 million for the first half of the year (first half of 2024: EUR 243.6 million).

The Plastics segment deteriorated significantly once again in the middle of the year, generating an operating result of EUR -1.9 million, which was lower than in the first half of the previous year (first half of 2024: EUR 1.2 million). The second quarter of 2025 accounts for EUR -1.5 million of this amount (Q2 2024: EUR 0.8 million). Sales revenue also declined significantly to EUR 9.2 million and EUR 18.9 million, respectively, compared with the prior-year figures (Q2-2024: EUR 11.9 million; first half of 2024: EUR 24.2 million).

Operating cash flow totaled EUR 32.7 million in the second quarter of 2025 (Q2-2024: EUR -5.9 million), while free cash flow amounted to EUR 22.8 million (Q2-2024: EUR -18.3 million). At the end of the first half of the year, operating cash flow stood at EUR 24.6 million (first half of 2024: EUR 5.5 million) and free cash flow at EUR 5.1 million (first half of 2024: EUR -18.5 million). On average, less was spent on raw materials in the first half of 2025 than in the same period of the previous year. Net working capital requirements changed accordingly, easing the strain on operating cash flow. Significant but nevertheless reduced investments also had less of an impact on free cash flow, leading to an improvement.  

Total assets amounted to EUR 972.0 million as of June 30, 2025 (December 31, 2024: EUR 1,014.9 million). Equity decreased slightly during the same period and amounted to EUR 449.9 million (December 31, 2024: EUR 468.6 million). As of June 30, 2025, the company's equity ratio was 46.3% (December 31, 2024: 46.2%).

The company got off to a solid start to the fiscal year, but lost momentum in the second quarter of 2025. As a result, we achieved EBITDA in line with the lower end of the expected range (€85.0 million). If raw material prices and volume demand develop in line with our expectations in the second half of the year, as do product prices, an overall result within the guidance range would be possible.

At the same time, the current overall situation (economic developments; competitive situation; tariff barriers; armed conflicts along important trade routes) certainly introduces unknowns into this equation. A more accurate assessment will therefore only be possible if visibility improves significantly in the coming months. We will refine our expectations accordingly. The final financial figures and further information on business development in 2025 to date will be published as planned in the half-year report on August 15, 2025.

 

Contact information:

H&R GmbH & Co. KGaA, Head of Investor Relations/Communications, Ties Kaiser

Neuenkirchener Strasse 8, 48499 Salzbergen

Tel.: +49 40 43218-321, Fax: +49 40 43218-390

e-mail: ties.kaiser@hur.com ; www.hur.com

 

H&R GmbH & Co. KGaA:

H&R KGaA is a specialty-chemicals company listed on the Frankfurt Stock Exchange's Prime Standard segment. It develops and manufactures chemical and pharmaceutical specialty products based on fossil, biological, synthesized and recycled hydrocarbons, and produces high-precision plastic parts.

 

Forward-looking statements and forecasts:

This press release contains forward-looking statements. The statements are based on the current estimates and forecasts by the Executive Board and the information available to the Board at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this press release.

 



End of Inside Information

25-Jul-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: H&R GmbH & Co. KGaA
Neuenkirchener Str. 8
48499 Salzbergen
Germany
Phone: +49 (0)40 43 218 321
Fax: +49 (0)40 43 218 390
E-mail: investor.relations@hur.com
Internet: www.hur.com
ISIN: DE000A2E4T77
WKN: A2E4T7
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Hamburg; Regulated Unofficial Market in Berlin, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2174574

 
End of Announcement EQS News Service

2174574  25-Jul-2025 CET/CEST

Analysen zu H&R GmbH & Co. KGaAmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

H&R GmbH & Co. KGaA 4,98 1,22% H&R GmbH & Co. KGaA